Better business coming in than going out: management describes the quality of new intake visibly exceeding what it is re
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that the business being taken in now is of visibly higher quality than the business it is finishing/replacing, with a contrast between incoming and outgoing business, and that the turnover is real and current, with results improving as the mix turns over. Let's examine the transcript for such a contrast. The call discusses MRD and Immune Medicine. For MRD, they talk about volume growth, ASP increases, expansion into DLBCL, Epic integration, community penetration. They mention ASP trending towards $1700 per test, but that's a future expectation. They talk about increasing penetration, but not necessarily a contrast between new and old business quality. For Immune Medicine, they discuss pharma services growth, drug discovery, Genentech partnership. They mention that Genentech amortization is a headwind, but that's about revenue recognition, not about quality of new business. The question asks: does management convey that the business being taken in now is of visibly higher quality than the business it is finishing/replacing? That is, is there a contrast between new incoming work and older business still in results, with the new being better priced, margined, etc., and that as the old rolls off, results improve on strength of already taken business? Looking for specific statements. For example, in MRD, they talk about ASP increasing, but that's due to pricing agreements and collection performance, not necessarily a change in mix of business. They talk about community penetration increasing, but that's volume growth, not necessarily higher quality. They talk about DLBCL launch, but that's a new indication, not necessarily better economics. They mention that MRD pharma partnerships are growing, but not a contrast. In Immune Medicine, they talk about pharma services growth, but no contrast with older business. They mention Genentech amortization headwind, but that's about accounting, not about quality of new business. The question specifically asks about a contrast between incoming and outgoing business. I don't see management explicitly stating that the new business is better than the old business in terms of economics, margins, terms, etc. They talk about growth and expansion, but not a direct comparison of quality between what's coming in and what's going out.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| BBD | Banco Bradesco S.A. | Q3 2022 | 2022-11-09 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
HSTM · Q3 2017 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting incoming business against outgoing: - Patient Experience: "Existing clients also continue to convert from a phone modality to email and SMS text surveying modality... This conversion trend to continue... expected to have a positive impact... on patient experience margins." (lower price, higher margin shift already happening) - Provider Solutions: "the move from installed software sales to software as service sales... challenge revenue growth... but not profitability growth" and "backlog of unimplemented customers... significantly reduced" - Laerdal/HeartCode: "the new product we believe is right now based on contracts.
GFS · Q3 2021 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting the incoming business with the outgoing: compute revenue is declining "as expected" due to customers shifting to smaller nodes, while "newer high-margin customer designs" are ramping in 2H 2022 to offset it. They tie this directly to mix improvement from "d differentiated solutions become a larger portion" and "feature-rich" platforms (FDX, RF SOI, silicon photonics) growing while feature-rich CMOS is flat or down. LTAs signed now carry "pricing improvements" baked in for 2022+, with new agreements committing future capacity at those better terms.
CYBR · Q3 2021 → YESThe question is about whether management conveys that the new business they're taking in is of higher quality than the old business they're replacing, and that as the old rolls off, results will impro...YES Management explicitly contrasts the incoming subscription business (new logos, SaaS bookings, Privileged Cloud, EPM) as higher-quality than the outgoing perpetual license business it is replacing. They describe it as delivering “faster type of value,” “higher lifetime value over time,” and “more users and more products faster ,” while noting that the current revenue and profitability headwind from the mix shift is “obscuring the P&L” and that results will improve once the transition completes.